Phase 2 Study of Tremelimumab Plus Durvalumab Alone or With Radiation for SCLC

Share this content:
Researchers are evaluating the efficacy of tremelimumab plus durvalumab alone or with radiation therapy among patients with SCLC.
Researchers are evaluating the efficacy of tremelimumab plus durvalumab alone or with radiation therapy among patients with SCLC.

Title: A Randomized Study of Tremelimumab Plus Durvalumab Combination With or Without Radiation in Relapsed Small Cell Lung Cancer1

Principal Investigator: Taofeek K. Owonikoko, MD, PhD, Emory University

Description: For this open-label phase 2 study (ClinicalTrials.gov Identifier: NCT02701400), researchers are evaluating the efficacy of tremelimumab plus durvalumab alone or with radiation therapy among patients with small-cell lung cancer (SCLC) who fail first-line therapy.

Patients will be randomly assigned to receive intravenous (IV) tremelimumab and durvalumab over 1 hour on day 1 every 4 weeks for up to 1 year, or stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy for 5 days over 1 week or for 3 fractions every other day for 1 week plus IV tremelimumab and durvalumab.

The primary outcomes are progression-free survival and the objective response rate.

The estimated study enrollment is 20 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact

information, visit https://clinicaltrials.gov/ct2/show/NCT02701400.

Status: Open and recruiting patients as of February 21, 2018.

This study is sponsored by Emory University.

Reference

  1. ClinicalTrials.gov. Tremelimumab and durvalumab with or without radiation therapy in patients with relapsed small cell lung cancer. NCT02701400. https://clinicaltrials.gov/ct2/show/NCT02701400. Accessed February 21, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs